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Abstract 
Hodgkin’s disease is, in general, a lymph
node-based  disease.  It  usually  starts  in  an
area  within  the  lymphatic  system  and
spreads,  in  an  orderly  manner,  along  the
lymph  atic  chain  to  contiguous  lymph  node
areas. There have been sporadic case reports
of acute liver failure caused by hematological
malignancies. Generally, liver failure is a fea-
ture of stage IV end-stage disease, when it
occurs in lymphoma. Thus, hepatic involve-
ment  usually  occurs  late  in  the  course  of
Hodgkin’s disease or with advanced-stage dis-
ease, and primary presentation in the liver
with acute liver failure is extremely rare. In
most cases, the diagnosis was made at aut  -
opsy.  We  describe  a  patient  with  Hodgkin’s
disease  presenting  with  acute  liver  failure.
This is a very unusual Hodgkin’s disease form
of presentation, because the acute liver fail-
ure was the presenting feature of the disease.
Furthermore,  the  lymphoma  occurred  as  a
very late relapse, twenty years after the first
diagnosis. To the best of our knowledge, such
a case has not been described to date. 
Case Report
A  59-year-old  woman  was  diagnosed  in
May 1986 as suffering from stage IVA nodular
sclerosis Hodgkin’s disease (HD) with liver
and  spleen  involvement.  She  received
Mantel-like radiotherapy including submen-
tal, cervical, supra- and infraclavicular, axil-
lary, hilar, and mediastinal lymph nodes. In
October 1986, an exploratory laparotomy was
performed,  which  showed  retroperitoneal
lymph node involvement and liver and splenic
infiltration.  Then,  splenectomy  and  treat-
ment  with  12  cycles  of  CMOP/ABVD
chemotherapy were performed. After finish-
ing treatment, the presence of liver involve-
ment (owing to the initial presence of infil-
tration  of  the  liver)  was  re-evaluated.
Histological examination of the liver showed
persistence of infiltration of HD. The patient
was referred to another center where a sec-
ond-line  therapy  with  six  courses  of
chemotherapy  (CEP-CCNU,  etoposide,  and
predmustine) was initiated. At the end of the
treatment,  the  patient  was  in  complete
remission. She was controlled in the refer-
ence  center  during  the  ten  years  after  the
initial diagnosis, when she was considered
cured of her disease. After this, there were
no  controls  or  subsequent  additional  scans
done. In September 2009, the patient com-
plained  of  asthenia,  dyspnea,  nocturnal
sweats, and 39ºC fever. She was admitted to
hospital with jaundice.
The complete blood picture showed hemo-
globin, 10.7 g/dL; platelet count, 305ﾥ109/L;
and leukocyte count, 8.6ﾥ109/L. Serum bio-
chemistry showed total protein, 5.3g/dL (ref-
erence  values:  6.0-8.0  g/dL);  albumin,  1.8
g/dL (reference values: 3.5-4.6g/dL); alkaline
phosphatise, 1257 U/L (reference values: 70-
270 UI/L); ferritine, 4207 ng/mL (reference
values:  24-336  ng/mL).  Liver  enzymes  and
bilirubin  were  significantly  elevated:  total
bilirubin, 4.0 mg/dL (reference values: 0.2-
1.2 mg/dL;); direct, 2.4 mg/dL (normal value:
<0.3 mg/dL); GOT, 76 UI/L (reference values
5-37 UI/L); GPT, 74 UI/L (reference values: 5-
40 UI/L); gamma-GT, 327 UI/L (reference val-
ues 5-50 UI/L). Serum ʱ-fetoprotein and car-
cino-embryonic  antigen  levels  were  within
normal limits. Serology for HIV and hepatitis
B and C were negative. Serology for CMV and
EBV  were  IgM-negative  and  IgG-positive.
Repeat blood cultures and sepsis work-up did
not reveal any focus of infection. 
A  body  computer  tomography  (CT)  scan
showed  retroperitoneal  enlarged  lymph
glands,  without  focal  liver  lesions  or  other
lymphadenopathies. The study was extended
by a PET-CT scan. It showed, in addition to
the  lymph  nodes,  a  liver  hypermetabolic
lesion  in  the  right  lobe,  segment  VIII,
suggest  ive of malignancy. A liver needle biop-
sy was performed. The histological examina-
tion of the liver showed portal and porto-por-
tal fibrous septa and atypical large mononu-
clear  Hodgkin’s  cells  and  typical  Reed-
Sternberg (RS) cells CD30+ CD15+, LMP CD
45– (Figure 1). Bone marrow was also affect-
ed. 
The diagnosis of a very late relapse of HD
with  liver  involvement  was  made  and  the
ABVD  protocol  (Adriamycin-bleomycin-vin-
blastine-dacarbazine)  was  given.  Two  days
after  chemotherapy,  the  patient’s  general
condition  progressively  deteriorated  with
massive pleural effusion, renal failure, and
acute liver failure with hepatic encephalop  -
athy. The patient died in spite of being moved
to the intensive care unit. The family refused
a postmortem examination. 
Discussion
Hepatic involvement in HD usually occurs
late  in  the  course  of  the  disease  or  with
advanced-stage disease, and primary presenta-
tion in the liver is extremely rare.1,3 Acute liver
failure (ALF) can result from a wide variety of
causes, of which viral and toxin-induced hepa-
titis are the most common. ALF also has been
reported  in  patients  with  malignant  infiltra-
tion of the liver by malignancies such as lung,
breast, melanoma, and others. Hematological
malignancies are the most common underly-
ing  etiology,  including  Hodgkin’s  lymphoma,
non-Hodgkin’s  lymphoma,  malignant  histio  -
cytosis, and leukemia. However, it is distinctly
uncommon for ALF to be the initial manifest  -
ation of a malignant process.2-4
Hepatic infiltration by hematological malig-
nancies occurs in 15-22% of cases, but very
rarely causes ALF. A review showed that only 18
of 4020 patients (i.e. 0.44%) admitted over a
period of 18 years at a liver failure unit had
ALF secondary to malignant infiltration. The
etiology was HD in three patients. Most of the
patients in this series had evidence of extra-
hepatic  involvement  of  their  disease,  either
with  peripheral  or  intra-abdominal  lymph  -
adenopathy,  bone  marrow  infiltration,  or
splenomegaly.2 Infiltrations  by  lymphoma  of
small  intrahepatic  bile  ducts  may  result  in
extensive  cholangitis,  duct  necrosis,  and
tumor obstruction of hepatic venules. On the
other  hand,  tumor  infiltrations  of  hepatic
parenchyma  may  lead  to  a  critical  mass  of
hepatocyte  destruction  and  subsequent  ALF.
Hepatic failure can occur even if cells had infil-
trated  extensively  into  the  liver,  and  conse-
quently hepatic failure and jaundice were con-
sidered  the  result  of  massive  liver  involve-
ment.3,4
Making a diagnosis of hepatic infiltration in
patients presenting with ALF in such cases gen-
erally is difficult, and hence HD can be diag-
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nosed  late.  However,  early  diagnosis  is  very
important because it is possible that quick insti-
tution  of  specific  chemotherapy  may  reverse
liver disease. Clinical and laboratory findings
are not helpful for differential diagnosis. All of
them may be seen in a number of primary liver
diseases. Ultrasonography and CT scans seem
to be inadequate in diagnosing hepatic lymph  -
oma.4 To  diagnose  hepatic  involvement,  the
presence of mononuclear variants of RS cells in
an appropriate background is sufficient if the
diagnosis  of  HD  has  been  established  in  a
lymph node, but if liver tissue is the only mater  -
ial examined, demonstration of classical multi-
nucleated RS cells is required.1
As the liver has limited tolerance to radio-
therapy, and surgery is only feasible for solitary
lesions, the choice of treatment in this case
with disseminated liver involvement was com-
bined  chemotherapy.1 Conventional-dose 
che  motherapy  has  demonstrated  very  poor
results  in  refractory  and  early  relapsed
patients after first-line chemotherapy. For late
relapsed  patients  (<12  months),  salvage
chemotherapy with conventional-dose therapy
shows  a  35%  probability  of  overall  survival
(OS) five years after therapy. The remission
rate is greatest in patients with late relapse
(75% vs. 55% for early relapse vs. 35% for pri-
mary refractory Hodgkin’s lymphoma).6,7 Our
case demonstrates that relapsing lymphoma in
the liver, even in patients without evidence of
extrahepatic  malignancy,  should  be  included
in the differential diagnosis of ALF and treated
accordingly. In the presence of lymphadenop  -
athy and hepatomegaly in ALF patients, hema-
tological  malignancies  should  be  taken  into
account,  and  liver  and  lymph  node  biopsies
should be performed as early as possible. This
is the only way to reach the correct diagnosis
and start appropriate chemotherapy, which can
be life-saving. 
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Figure 1. Portal infiltrate by Hodgkin’s and
pleomorphic  Reed-Sterberg  cells  in  the
liver. (Hematoxylin-and-eosin stain; 200X
magnification.)